Virtual reality exposure therapy advances and potential for clinical and experimental use
- PMID: 39020139
- PMCID: PMC11526015
- DOI: 10.1038/s41386-024-01930-2
Virtual reality exposure therapy advances and potential for clinical and experimental use
Erratum in
-
Correction: Neuropsychopharmacology Volume 50 Issue 1.Neuropsychopharmacology. 2025 May;50(6):1019-1020. doi: 10.1038/s41386-025-02087-2. Neuropsychopharmacology. 2025. PMID: 40108440 Free PMC article. No abstract available.
Conflict of interest statement
Dr. Barbara Rothbaum has received Research/Grants from Wounded Warrior Project, NIH, Department of Defense, NSF, Bob Woodruff Foundation, MAPS; is a stockholder in Virtually Better; has been paid as a consultant by Otsuka, Psychwire, Senseye, MAPS, Jazz Pharmaceuticals, GoodCap, Transcend, Penumbra; serves on the Scientific Advisory Boards for Anxiety and Depression Association of America (ADAA), National Center for PTSD; serves on the Board of Directors for GratitudeAmerica; receives Royalties from Oxford University Press, APPI, Emory University. Emory Healthcare Veterans Program is supported by a grant from the Wounded Warrior Project. The terms of these arrangements have been reviewed and approved by Emory University in accordance with its conflict of interest policies. Dr. Jacob Rothbaum reports no competing interests.
References
-
- Rothbaum BO, Hodges LF, Kooper R, Opdyke D, Williford JS, North M. Effectiveness of computer-generated (virtual reality) graded exposure in the treatment of acrophobia. Am J Psychiatry. 1995;152:626–8. - PubMed
-
- Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Zimand E, Hodges L, et al. Facilitation of psychotherapy with D-cycloserine, a putative cognitive enhancer. Arch Gen Psychiatry. 2004;61:1136–44. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
